130 related articles for article (PubMed ID: 3152957)
21. Pharmacokinetics of methotrexate in children with acute lymphocytic leukemia.
Najjar TA; al Fawaz IM
Chemotherapy; 1993; 39(4):242-7. PubMed ID: 8325125
[TBL] [Abstract][Full Text] [Related]
22. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
23. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
[TBL] [Abstract][Full Text] [Related]
24. Remission induction of meningeal leukemia with high-dose intravenous methotrexate.
Balis FM; Savitch JL; Bleyer WA; Reaman GH; Poplack DG
J Clin Oncol; 1985 Apr; 3(4):485-9. PubMed ID: 3856631
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic modeling of plasma and cerebrospinal fluid methotrexate after high-dose intravenous infusion in children.
Chatelut E; Roche H; Plusquellec Y; Peyrille F; De Biasi J; Pujol A; Canal P; Houin G
J Pharm Sci; 1991 Aug; 80(8):730-4. PubMed ID: 1791530
[TBL] [Abstract][Full Text] [Related]
26. CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g/m2 methotrexate. A study from the EORTC Children's Leukemia Cooperative Group.
Milano G; Thyss A; Serre Debeauvais F; Laureys G; Benoit Y; Deville A; Dutour C; Robert A; Otten J; Behar C
Eur J Cancer; 1990 Apr; 26(4):492-5. PubMed ID: 2141516
[TBL] [Abstract][Full Text] [Related]
27. [Studies of methotrexate pharmacokinetics in children with neoplasms of the hematopoietic system after administration of different doses of the drug].
Wysocki M; Krzyzanowski M; Ozyński T; Pilecki O; Balcar-Boroń A; Szadujkis-Szadurski L
Acta Haematol Pol; 1992; 23(3):179-83. PubMed ID: 1492542
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of methotrexate given intrathecally to children with acute lymphoblastic leukemia.
Skibińska L; Daszkiewicz P; Michalewska D; Radwańska U
Pol J Pharmacol Pharm; 1988; 40(2):135-43. PubMed ID: 3237563
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
Kearns CM; Blakley RL; Santana VM; Crom WR
Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
[TBL] [Abstract][Full Text] [Related]
30. High-dose methotrexate in childhood all.
Moe PJ; Holen A
Pediatr Hematol Oncol; 2000 Dec; 17(8):615-22. PubMed ID: 11127393
[TBL] [Abstract][Full Text] [Related]
31. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.
Borsi JD; Moe PJ
Cancer; 1987 Jul; 60(1):5-13. PubMed ID: 3472638
[TBL] [Abstract][Full Text] [Related]
32. Correlation of cerebrospinal fluid beta-glucuronidase activity with plasma methotrexate concentrations in leukemic children receiving high-dose methotrexate.
Vlacha V; Eliopoulou M; Haidas S; Beratis NG
Pediatr Blood Cancer; 2004 Apr; 42(4):350-6. PubMed ID: 14966832
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients.
Rodman JH; Sunderland M; Kavanagh RL; Ochs J; Yalowich J; Evans WE; Rivera GK
Cancer Res; 1990 Jul; 50(14):4267-71. PubMed ID: 2194652
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
[TBL] [Abstract][Full Text] [Related]
35. Changes in plasma methionine and total homocysteine levels in patients receiving methotrexate infusions.
Broxson EH; Stork LC; Allen RH; Stabler SP; Kolhouse JF
Cancer Res; 1989 Nov; 49(21):5879-83. PubMed ID: 2790801
[TBL] [Abstract][Full Text] [Related]
36. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate.
Refsum H; Wesenberg F; Ueland PM
Cancer Res; 1991 Feb; 51(3):828-35. PubMed ID: 1988122
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after high-dose (33.6 g/m2) methotrexate therapy.
Slørdal L; Kolmannskog S; Prytz PS; Moe PJ; Aarbakke J
Pediatr Hematol Oncol; 1986; 3(2):127-34. PubMed ID: 3153222
[TBL] [Abstract][Full Text] [Related]
38. Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral mucositis.
Albertioni F; Rask C; Schroeder H; Peterson C
Anticancer Drugs; 1997 Feb; 8(2):119-24. PubMed ID: 9073308
[TBL] [Abstract][Full Text] [Related]
39. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
Damon LE; Plunkett W; Linker CA
Cancer Res; 1991 Aug; 51(16):4141-5. PubMed ID: 1868435
[TBL] [Abstract][Full Text] [Related]
40. Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration.
Balis FM; Blaney SM; McCully CL; Bacher JD; Murphy RF; Poplack DG
Cancer Chemother Pharmacol; 2000; 45(3):259-64. PubMed ID: 10663645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
